Early cancer cachexia phenotype predicts survival of advanced urothelial cancer patients treated with pembrolizumab.

Early cancer cachexia phenotypes were significantly associated with the survival of aUC patients treated with pembrolizumab. In contrast to the very early progression and poor prognosis in the MFW group, long-term survival can be expected in the NW/FW groups.